Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy.

Frontiers in immunology - 1 Jan 2021

Mehta Palak H, Fiorenza Salvatore, Koldej Rachel M, Jaworowski Anthony, Ritchie David S, Quinn Kylie M

Abstract excerpt

A range of emerging therapeutic approaches for the treatment of cancer aim to induce or augment endogenous T cell responses. Chimeric antigen receptor (CAR) T cell therapy (CTT) is one such approach that utilises the patient's own T cells, engineered ex vivo to target cell surface antigens, to eliminate haematological malignancies. Despite mediating high rates of responses in some clinical trials, this approach...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Decision-Making
Share to Genetic Therapy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Health Status

Share to Hematologic Neoplasms

Share to Immunotherapy, Adoptive

Share to Patient Selection

Share to Receptors, Chimeric Antigen

Share to T-Lymphocytes

Source

Open in PubMed Open full text

Identifiers

PMID: 34899742
DOI: 10.3389/fimmu.2021.780442
PMCID: PMC8658247

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy.PMID 34899742Read ↗

Healthy B cells: allies or adversaries of CAR-T cell immunotherapy?Semantic proximity Read ↗

Empowering the Potential of CAR-T Cell Immunotherapies by Epigenetic ReprogrammingSemantic proximity Read ↗

CAR T cell therapy: newer approaches to counter resistance and costSemantic proximity Read ↗

Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors.Semantic proximity Read ↗

Chimeric Antigen Receptor T-Cell Therapy: What We Expect SoonSemantic proximity Read ↗

Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T‐cells (CAR‐T): A comprehensive review on incidence, risk factors and current managementSemantic proximity Read ↗

Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies.Semantic proximity Read ↗

Harnessing T cell exhaustion and trogocytosis to isolate patient-derived tumor-specific TCRSemantic proximity Read ↗

CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cellsSemantic proximity Read ↗

Use of Mass Cytometry to Profile Human T Cell Exhaustion.Semantic proximity Read ↗

Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to managementSemantic proximity Read ↗

Tumor-Specific CD8 <sup>+</sup> T Cells from the Bone Marrow Resist Exhaustion and Exhibit Increased Persistence in Tumor-Bearing Hosts as Compared to Tumor Infiltrating LymphocytesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.